Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported that its shares fell 25% on Tuesday following the release of top‑line data from the 12‑week Phase 2 CIRRUS‑HCM trial evaluating the oral cardiac sarcomere modulator EDG‑7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). The trial enrolled a total of 53 patients, comprising 20 with obstructive HCM and 33 with nonobstructive HCM. In the obstructive cohort, 90% of patients demonstrated improvement in hemodynamic measures, and 74% achieved either normalization of NT‑proBNP levels or a reduction of at least 50% from baseline. In the nonobstructive cohort, 88% of patients achieved normalization of NT‑proBNP or a ≥50% reduction. EDG‑7500 is described as an oral, selective cardiac sarcomere modulator intended to slow early contraction velocity and enhance cardiac relaxation in symptomatic HCM. The company observed no relationship between drug exposure and left ventricular ejection fraction (LVEF), with no LVEF values falling below 50% during the study. Safety data indicated the drug was generally well tolerated; nearly all adverse events were mild to moderate, and two new‑onset atrial fibrillation events were reported, both judged unrelated to the investigational product by investigators. Based on these results, Edgewise stated that the data support progression of EDG‑7500 into Phase 3 clinical development, with the Phase 3 program targeted to commence in the fourth quarter of 2026.